About
Azevan Pharmaceuticals develops vasopressin V1a receptor antagonists as targeted treatments for pathological aggression and neurological injury in CNS disorders, including Huntington's disease, Fragile X syndrome, intermittent explosive disorder, and traumatic brain injury.
Explore Azevan's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.